BeOne Medicines (NASDAQ:ONC) Given New $446.00 Price Target at Barclays

BeOne Medicines (NASDAQ:ONC) had its price objective raised by Barclays from $415.00 to $446.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other equities research analysts also recently commented on the stock. TD Cowen boosted their target price on shares of BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Wolfe Research reiterated an “outperform” rating and set a $370.00 target price on shares of BeOne Medicines in a research report on Monday, August 10th. JPMorgan Chase & Co. lifted their price target on shares of BeOne Medicines from $425.00 to $445.00 and gave the company an “overweight” rating in a report on Thursday, October 1st. Finally, Citigroup restated an “outperform” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Sixteen equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $434.79.

BeOne Medicines Price Performance

Shares of BeOne Medicines stock traded up $19.71 during midday trading on Friday, hitting $406.96. 941,725 shares of the company were exchanged, compared to its average volume of 364,122. The firm has a 50 day simple moving average of $363.49 and a 200-day simple moving average of $326.34. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. The firm has a market cap of $44.68 billion, a P/E ratio of 51.71 and a beta of 0.63. BeOne Medicines has a 52 week low of $253.95 and a 52 week high of $410.71.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.34 by $1.30. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.76 billion. Research analysts forecast that BeOne Medicines will post 8.99 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Xiaodong Wang sold 31,028 shares of the company’s stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $362.97, for a total transaction of $11,262,233.16. Following the transaction, the insider owned 31,028 shares in the company, valued at $11,262,233.16. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Oyler sold 54,892 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total transaction of $19,659,569.80. Following the sale, the chief executive officer directly owned 240,743 shares in the company, valued at approximately $86,222,105.45. This represents a 18.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 376,373 shares of company stock valued at $134,848,154 in the last 90 days. 6.19% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in shares of BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after purchasing an additional 26,441 shares in the last quarter. Baird Financial Group Inc. increased its holdings in shares of BeOne Medicines by 5.5% in the second quarter. Baird Financial Group Inc. now owns 368,978 shares of the company’s stock valued at $105,148,000 after purchasing an additional 19,327 shares in the last quarter. Candriam S.C.A. increased its holdings in shares of BeOne Medicines by 31.7% in the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after purchasing an additional 62,470 shares in the last quarter. First Trust Advisors LP increased its holdings in shares of BeOne Medicines by 91.9% in the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after purchasing an additional 115,601 shares in the last quarter. Finally, Jennison Associates LLC raised its position in BeOne Medicines by 102.1% in the 1st quarter. Jennison Associates LLC now owns 154,465 shares of the company’s stock worth $45,871,000 after purchasing an additional 78,027 shares during the last quarter. 48.55% of the stock is owned by institutional investors.

BeOne Medicines News Roundup

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
• Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information

BeOne Medicines Company Profile

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.